New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
09:06 EDTMACKMerrimack announces positive clinical data for agent to treat breast cancer
Merrimack announced Phase I clinical trial results for MM-302, the company's agent for the treatment of advanced HER2 positive breast cancer. The findings demonstrated preliminary safety and tolerability.
News For MACK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 25, 2015
07:06 EDTMACKMerrimack's MM-398 NDA granted priority review by FDA
Merrimack (MACK) and Baxalta Incorporated, a wholly-owned subsidiary of Baxter (BAX) announced that the New Drug Application for MM-398 has been accepted for review by the FDA. Merrimack is seeking U.S. marketing approval of MM-398 for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. In addition, the FDA has classified the NDA as having Priority Review status. The FDA has set a goal of October 24 to take action under the Prescription Drug User Fee Act. The European Medicines Agency has also accepted for review a Marketing Authorization Application for MM-398 for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. The acceptance of the MAA marks the beginning of the review process in the European Union for MM-398 in this indication.
June 19, 2015
05:40 EDTMACKTESARO a favorite stock for second half of year at Mizuho
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use